Yesterday
Today
Tomorrow
News
2023
May
22
Apnimed Cracks Sleep Apnea Puzzle, Hits Primary Goal in Phase 2 Study
Read +
1
Casana Receives FDA Clearance for Heart Health Smart Toilet Seat
Read +
2023
April
26
Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-Ascending Dose Cohorts Study
Read +
25
Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington’s Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual Meeting
Read +
2023
February
24
Aural Analytics Speech Technology Signaled Slowing of Decline in ALS Patients’ Speech and Bulbar Function in Platform Trial Evaluating Pridopidine
Read +
23
Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
Read +
17
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
Read +
2023
January
24
Geneoscopy Submits Premarket Approval Application to FDA for its Noninvasive Colorectal Cancer RNA Biomarker Screening Test
Read +
17
Blood Cancer Patient With Months To Live Is Now ‘Better Than Ever’ Thanks to Wonder Pill
Read +
17
Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm
Read +
17
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
Read +
10
Geneoscopy’s Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial
Read +
9
Positive Results From Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1
Read +
2022
December
19
F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections
Read +
11
CellCentric Presents Early Clinical Data at ASH
Read +
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Disable all
Accept all